B cell responses to HIV and the development of human monoclonal antibodies (Q36048830)

11 August 2017

1 reference

title

B cell responses to HIV and the development of human monoclonal antibodies (English)

1 reference

11 August 2017

J. E. Boyd

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1572084

10 October 2022

K. James

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1572084

10 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1572084

10 October 2022

publication date

1 May 1992

1 reference

Clinical and Experimental Immunology

11 August 2017

1 reference

11 August 2017

88

1 reference

11 August 2017

2

1 reference

11 August 2017

189-202

1 reference

Long-Term Human Immunodeficiency Virus Infection in Asymptomatic Homosexual and Bisexual Men with Normal CD4+ Lymphocyte Counts: Immunologic and Virologic Characteristics

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Neuronal injury due to HIV-1 envelope protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Antibody-dependent cellular cytotoxicity specific for the envelope antigens of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Patterns of antibody response in individuals infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Clinical uses of intravenous immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Characterization and large production of human monoclonal antibodies against the HIV-1 envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Antilymphocyte antibodies and seropositivity for retroviruses in groups at high risk for AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB03061.X

Generation of human monoclonal antibodies to human immunodeficiency virus

21 January 2018

1 reference

12 December 2020

Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS.

1 reference

12 December 2020

Monoclonal antibodies to HIV in a non-infected, immunised volunteer

1 reference

12 December 2020

Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals

1 reference

12 December 2020

B-cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters

1 reference

12 December 2020

Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects

1 reference

12 December 2020

Synthetic peptides homologous to HIV transmembrane glycoprotein suppress normal human lymphocyte blastogenic response.

1 reference

12 December 2020

Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides

1 reference

12 December 2020

IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages

1 reference

12 December 2020

Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization

1 reference

12 December 2020

Heterogeneity of human immunodeficiency virus cell-associated antigens and demonstration of virus type specificities of human antibody responses

1 reference

12 December 2020

Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus

1 reference

12 December 2020

Analysis of human serum antibodies to human immunodeficiency virus (HIV) using recombinant ENV and GAG antigens

1 reference

12 December 2020

Human monoclonal antibody production. Current status and future prospects

1 reference

12 December 2020

In vitro stimulation prior to fusion generates antigen-binding human-human hybridomas

1 reference

12 December 2020

Serum IgD elevation is an early marker of B cell activation during infection with the human immunodeficiency viruses.

1 reference

12 December 2020

Analysis of the antigen- and mitogen-induced differentiation of B lymphocytes from asymptomatic human immunodeficiency virus-seropositive male homosexuals. Discrepancy between T cell-dependent and T cell-independent activation

1 reference

12 December 2020

Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages

1 reference

12 December 2020

Construction of reshaped human antibodies with HIV-neutralizing activity.

1 reference

12 December 2020

Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group

1 reference

12 December 2020

Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro

1 reference

12 December 2020

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein

1 reference

12 December 2020

IgG subclass responses to human immunodeficiency virus-1 antigens: lack of IgG2 response to gp41 correlates with clinical manifestation of disease

1 reference

12 December 2020

B cell activation during HIV-1 infection. II. Cell-to-cell interactions and cytokine requirement

1 reference

12 December 2020

Development of microfusion techniques to generate human hybridomas

1 reference

12 December 2020

Response of mononuclear cells from HIV-infected patients to B-cell mitogens: correlation with immunological and clinical features of disease progression

1 reference

12 December 2020

Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex

1 reference

12 December 2020

Human monoclonal antibodies and engineered antibodies in the management of cancer

1 reference

12 December 2020

A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS.

1 reference

12 December 2020

Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients

1 reference

12 December 2020

Relationship between immunoglobulin production and immortalization by Epstein Barr virus.

1 reference

12 December 2020

The optimal technological approach to the development of human hybridomas

1 reference

12 December 2020

1 reference

12 December 2020

HIV-2 antisera cross-neutralize HIV-1.

1 reference

12 December 2020

Highly immunoreactive antigenic site in a hydrophobic domain of HIV-1 gp41 which remains undetectable with conventional immunochemical methods

1 reference

12 December 2020

Reshaping human antibodies for therapy

1 reference

12 December 2020

Monoclonal antibodies to human immunodeficiency virus: their relation to the patterns of lymph node changes in persistent generalized lymphadenopathy and AIDS.

1 reference

12 December 2020

Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role

1 reference

12 December 2020

Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS

1 reference

12 December 2020

A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity

1 reference

12 December 2020

Replication and pathogenesis of the AIDS virus.

1 reference

12 December 2020

Immunoregulatory activities of human immunodeficiency virus (HIV) proteins: effect of HIV recombinant and synthetic peptides on immunoglobulin synthesis and proliferative responses by normal lymphocytes

1 reference

12 December 2020

Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases.

1 reference

12 December 2020

Characterization of HIV-1 neutralization escape mutants

1 reference

12 December 2020

Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products

1 reference

12 December 2020

Mapping of IgG subclass and T-cell epitopes on HIV proteins by synthetic peptides.

1 reference

12 December 2020

HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection.

1 reference

12 December 2020

Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers

1 reference

12 December 2020

Individuals infected with HIV possess antibodies against IL-2

1 reference

12 December 2020

Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals

1 reference

12 December 2020

Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping

1 reference

12 December 2020

Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow

1 reference

12 December 2020

Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition.

1 reference

12 December 2020

Application of a human monoclonal antibody in a rapid competitive anti-HIV ELISA.

1 reference

12 December 2020

Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects

1 reference

12 December 2020

Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies

1 reference

12 December 2020

Antibody that inhibits human immunodeficiency virus reverse transcriptase and association with inability to isolate virus.

1 reference

12 December 2020

Neutralizing monoclonal antibodies to the AIDS virus

1 reference

12 December 2020

The effects of human immunodeficiency virus recombinant envelope glycoprotein on immune cell functions in vitro

1 reference

12 December 2020

Lymphocyte transformation response to pokeweed mitogen as a predictive marker for development of AIDS and AIDS related symptoms in homosexual men with HIV antibodies

1 reference

12 December 2020

Human monoclonal antibody against glycoproteins of human immunodeficiency virus

1 reference

12 December 2020

Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide.

1 reference

12 December 2020

Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus

1 reference

12 December 2020

Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin 2.

1 reference

12 December 2020

Stimulatory and inhibitory influences of human immunodeficiency virus on normal B lymphocytes

1 reference

12 December 2020

Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein.

1 reference

12 December 2020

Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations

1 reference

12 December 2020

HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis.

1 reference

12 December 2020

The significance of antilymphocyte antibodies in patients with acquired immune deficiency syndrome (AIDS) and their sexual partners.

1 reference

12 December 2020

Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry

1 reference

12 December 2020

Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs

1 reference

12 December 2020

Anti-lymphocyte antibodies in patients with the acquired immune deficiency syndrome

1 reference

12 December 2020

Characterization and epitope mapping of a human monoclonal antibody reactive with the envelope glycoprotein of human immunodeficiency virus.

1 reference

12 December 2020

Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope

1 reference

12 December 2020

Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.

1 reference

12 December 2020

Characterization of monoclonal antibodies against the human immunodeficiency virus (HIV) gag products and their use in monitoring HIV isolate variation

1 reference

12 December 2020

Neutralisation of HIV isolates by anti-idiotypic antibodies which mimic the T4 (CD4) epitope: a potential AIDS vaccine

1 reference

12 December 2020

Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor

1 reference

12 December 2020

Variable and conserved neutralization antigens of human immunodeficiency virus

1 reference

12 December 2020

Isotype, distribution and target analysis of lymphocyte reactive antibodies in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120.

1 reference

12 December 2020

Replication of the human immunodeficiency virus 1 and impaired differentiation of T cells after in vitro infection of bone marrow immature T cells

1 reference

12 December 2020

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

1 reference

12 December 2020

Human monoclonal antibody against a gag-coded protein of human immunodeficiency virus produced by a stable EBV-transformed cell clone.

1 reference

12 December 2020

Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance

1 reference

12 December 2020

Low numbers of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific serum antibody titers

1 reference

12 December 2020

In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus

1 reference

12 December 2020

Recognition of human immunodeficiency virus glycoproteins by natural anti-carbohydrate antibodies in human serum

1 reference

12 December 2020

Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies

1 reference

12 December 2020

Epitopes of human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins recognized by antibodies in the sera of HIV-1-infected individuals

1 reference

12 December 2020

An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection

1 reference

12 December 2020

In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein

1 reference

12 December 2020

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

1 reference

12 December 2020

Search for Epitope-Specific Antibody Responses to the Human Immunodeficiency Virus (HIV-1) Envelope Glycoproteins Signifying Resistance to Disease Development

1 reference

12 December 2020

Glycosylation Governs the Binding of Antipeptide Antibodies to Regions of Hypervariable Amino Acid Sequence within Recombinant gp120 of Human Immunodeficiency Virus Type 1

1 reference

12 December 2020

Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody

1 reference

12 December 2020

Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro

1 reference

12 December 2020

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies

1 reference

12 December 2020

Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region

1 reference

12 December 2020

Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain

1 reference

12 December 2020

Biological properties of anti-CD4 autoantibodies purified from HIV-infected patients

1 reference

12 December 2020

Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro

1 reference

12 December 2020

IgG subclass responses to a transmembrane protein (gp41) peptide in HIV infection

1 reference

12 December 2020

Strategy for the production of human monoclonal antibodies using in vitro activated B cells

1 reference

12 December 2020

Genetically engineered antibodies

1 reference

12 December 2020

Human immunodeficiency viruses and the pathogenesis of AIDS.

1 reference

12 December 2020

Human monoclonal antibodies: their potential, problems, and prospects

1 reference

12 December 2020

Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135).

1 reference

12 December 2020

In vitro synthesis of human immunodeficiency virus-specific antibodies in peripheral blood lymphocytes of infants

1 reference

12 December 2020

Localization of B-cell stimulatory activity of HIV-1 to the carboxyl terminus of gp41

1 reference

12 December 2020

Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody

1 reference

12 December 2020

Epitope mapping of the HIV-1 gag region with monoclonal antibodies

1 reference

12 December 2020

Identification of Conserved and Variant Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) gp120 by Human Monoclonal Antibodies Produced by EBV-Transformed Cell Lines

1 reference

12 December 2020

Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization

1 reference

12 December 2020

Prevalence of Antibodies to the Core Protein P17,aSerological Marker During HIV-1 Infection

1 reference

12 December 2020

Production and Characterization of a Human Monoclonal Antibody, Reactive with a Conserved Epitope on gp41 of Human Immunodeficiency Virus Type I

1 reference

12 December 2020

Inhibition of functional properties of tetanus antigen-specific T-cell clones by envelope glycoprotein GP120 of human immunodeficiency virus.

1 reference

12 December 2020

Production and characterization of human monoclonal antibodies against core protein p25 and transmembrane glycoprotein gp41 of HIV-1.

1 reference

12 December 2020

An anti-p24 monoclonal antibody shows cross-reactivity with multiple HIV-1 proteins.

1 reference

12 December 2020

Polyclonal B-cell activation reveals antibodies against human immunodeficiency virus type 1 (HIV-1) in HIV-1-seronegative individuals

1 reference

12 December 2020

Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits

1 reference

12 December 2020

Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain

1 reference

12 December 2020

Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro

1 reference

12 December 2020

Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals

1 reference

12 December 2020

A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization

1 reference

12 December 2020

B-cell immunodeficiency in acquired immune deficiency syndrome

1 reference

12 December 2020

Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines

1 reference

12 December 2020

Immunoregulatory subsets of the T helper and T suppressor cell populations in homosexual men with chronic unexplained lymphadenopathy

1 reference

12 December 2020

Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency Syndrome

1 reference

12 December 2020

Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion

1 reference

12 December 2020

Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases.

1 reference

12 December 2020

Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.

1 reference

12 December 2020

Neutralizing antibodies and the course of HIV-induced disease.

1 reference

12 December 2020

In vitro generation of an HTLV-III variant by neutralizing antibody

1 reference

12 December 2020

Diagnostic Utility of a Mouse Monoclonal Antibody (5-21-3) Employed as a Competitive Probe in an Immunoassay to Detect Antibody to HIV-1 gp41

1 reference

12 December 2020

Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection

1 reference

12 December 2020

Antibody responses in HIV infection

1 reference

12 December 2020

Humanized antibodies for antiviral therapy

1 reference

12 December 2020

Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning

1 reference

12 December 2020

Immune response to HIV p24 core protein during the early phases of human immunodeficiency virus infection

1 reference

12 December 2020

B-cell activation during HIV-1 infection. III. Down-regulating effect of mitogens

1 reference

12 December 2020

An inhibition enzyme immunoassay using a human monoclonal antibody (K14) reactive with gp41 of HIV-1 for the serology of HIV-1 infections

1 reference

12 December 2020

Isotypic restriction of the antibody response to human immunodeficiency virus

1 reference

12 December 2020

Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera

1 reference

12 December 2020

Characterization of serum neutralization response to the human immunodeficiency virus (HIV).

1 reference

12 December 2020

A hybridoma producing human monoclonal antibody specific for glycoprotein 120 kDa of human immunodeficiency virus (HIV-1.

1 reference

12 December 2020

A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells

1 reference

12 December 2020

Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping

1 reference

12 December 2020

Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity

1 reference

12 December 2020

Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell l

1 reference

12 December 2020

Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain

1 reference

12 December 2020

Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization

1 reference

12 December 2020

The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus

1 reference

12 December 2020

Human monoclonal antibody directed against gag gene products of the human immunodeficiency virus

1 reference

12 December 2020

Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.

1 reference

12 December 2020

Restricted heterogeneity of antibody to gp120 and p24 in AIDS

1 reference

12 December 2020

IgG subclass reactivity against human immunodeficiency virus (HIV) and cytomegalovirus in cerebrospinal fluid and serum from HIV-infected patients.

1 reference

12 December 2020

Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide

1 reference

12 December 2020

Therapeutic strategies with monoclonal antibodies and immunoconjugates

1 reference

12 December 2020

10.1111/J.1365-2249.1992.TB03061.X

Identifiers

DOI

1 reference

National Center for Biotechnology Information

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1572084

10 October 2022

1 reference